Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST – Get Rating) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,934,033 shares of the company’s stock after purchasing an additional 114,137 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 5.18% of Twist Bioscience worth $69,859,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Captrust Financial Advisors raised its holdings in Twist Bioscience by 101.3% during the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock worth $27,000 after buying an additional 382 shares during the period. Canada Pension Plan Investment Board boosted its stake in Twist Bioscience by 155.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock worth $52,000 after purchasing an additional 649 shares during the period. Lazard Asset Management LLC grew its position in Twist Bioscience by 73.4% during the 1st quarter. Lazard Asset Management LLC now owns 1,597 shares of the company’s stock worth $78,000 after purchasing an additional 676 shares in the last quarter. Sandia Investment Management LP purchased a new position in Twist Bioscience during the 3rd quarter worth approximately $88,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Twist Bioscience by 12.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,023 shares of the company’s stock valued at $106,000 after purchasing an additional 333 shares during the period.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on TWST. Evercore ISI upgraded Twist Bioscience from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $36.00 in a report on Tuesday, January 3rd. Robert W. Baird dropped their target price on Twist Bioscience from $33.00 to $29.00 in a report on Monday, February 6th. Barclays decreased their price target on shares of Twist Bioscience from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 6th. Scotiabank began coverage on shares of Twist Bioscience in a research note on Wednesday, January 4th. They issued a “sector outperform” rating and a $33.00 price objective on the stock. Finally, The Goldman Sachs Group decreased their target price on shares of Twist Bioscience from $50.00 to $43.00 and set a “neutral” rating for the company in a research note on Monday, February 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.
Twist Bioscience Stock Up 0.1 %
Twist Bioscience (NASDAQ:TWST – Get Rating) last released its quarterly earnings results on Friday, February 3rd. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.35. Twist Bioscience had a negative net margin of 99.23% and a negative return on equity of 27.35%. The business had revenue of $54.20 million for the quarter, compared to the consensus estimate of $54.47 million. During the same quarter last year, the firm earned ($0.91) EPS. Twist Bioscience’s revenue for the quarter was up 29.0% on a year-over-year basis. As a group, equities analysts forecast that Twist Bioscience Co. will post -3.89 earnings per share for the current fiscal year.
About Twist Bioscience
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC.
Featured Stories
- Get a free copy of the StockNews.com research report on Twist Bioscience (TWST)
- What is an IRA Account? All About IRAs
- Investing in Quantum Computing: A Guide
- Earnings Beat Proves Citigroup to be The Cheaper Bank Stock
- How to Invest in an IRA in 7 Simple Steps
- The Worst May Have Been Priced Into Amazon Stock, Upside Remains
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
